GIMBHI’s daily mental health update — 4/21/26

💊 Click Therapeutics lands $50M Series D from Boehringer to commercialize schizophrenia digital therapeutic (Click Therapeutics, GlobeNewswire) — 04/09/26
TL;DR: Boehringer is transferring CT-155 commercialization to Click Therapeutics alongside a $50M Series D, after Phase III CONVOKE showed a 62% relative improvement in negative symptoms of schizophrenia.

🧠 Beacon Biosignals upsizes Series B to $97M to scale brain data platform (Beacon Biosignals, GlobeNewswire) — 04/06/26
TL;DR: Boston-based Beacon Biosignals extended its Series B to $97M with new investors including Samsung Next and Palo Santo, advancing at-home EEG and AI analytics for neurology, psychiatry, and sleep medicine.

🏅 APA Labs launches Digital Badge Solutions Library to vet digital mental healthtools (APA News, American Psychological Association) — 04/14/26
TL;DR: APA Labs launched a searchable library of digital mental health tools evaluated with ORCHA on safety, privacy, and evidence, helping clinicians and users find trusted products in an unregulated market.

⚖️ Mental health parity remains elusive in 43 states, new Index finds (Sara Heath, TechTarget) — 04/16/26
TL;DR: The Kennedy Forum’s new Mental Health Parity Index shows enrollees in 43 states face fewer in-network mental health providers than physical health providers, with reimbursement rates 16–59% lower.

💊 Trump pushes psychedelics reform through health agencies in new executive order (Daniel Payne, STAT) — 04/18/26💊 Trump pushes psychedelics reform through health agencies in new executive order (Daniel Payne, STAT) — 04/18/26
TL;DR: Trump’s executive order directs the FDA to expedite psychedelics as breakthrough drugs and allow right-to-try access, with three priority review vouchers for serotonin 2a agonists coming next week.

📱 Excellent Brain launches Android version of ADHD neurofeedback platform (Excellent Brain Ltd., GlobeNewswire) — 04/14/26
TL;DR: Tel Aviv-based Excellent Brain released an Android version of its EEG-based neurofeedback platform for ADHD, expanding mobile access for clinics and individuals seeking cognitive training.

📈 Trilliant Health’s 2026 report finds behavioral health demand surged 62.6% since 2018 (Trilliant Health, Business Wire) — 04/14/26
TL;DR: Utilization hit 1,346 visits per 1,000 people, drug/alcohol-induced deaths are up 176% since 1999, and untreated mental illness cost $477.5B in 2024, projected to exceed $1.3T by 2040.

🎮 brainjo raises €2M seed funding for VR-based ADHD therapy for children (News Desk, HTWorld) — 04/20/26
TL;DR: Regensburg-based brainjo raised €2M led by High-Tech Gründerfonds to fund clinical trials and regulatory approval of its VR-based prescription ADHD therapy for children, targeting 2028 market launch.